PARP and PARG inhibitors in cancer treatment
D Slade - Genes & development, 2020 - genesdev.cshlp.org
Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …
genomic instability through radiotherapy and chemotherapy has been a powerful but …
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
A mounting body of evidence now indicates that PARP inhibitors have the potential to be
used as a foundation for both monotherapy and combination strategies across a wide …
used as a foundation for both monotherapy and combination strategies across a wide …
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
X Jiang, X Li, W Li, H Bai… - Journal of cellular and …, 2019 - Wiley Online Library
Abstract Poly (ADP‐ribose) polymerase (PARP) inhibitors have provided great clinical
benefits to ovarian cancer patients. To date, three PARP inhibitors, namely, olaparib …
benefits to ovarian cancer patients. To date, three PARP inhibitors, namely, olaparib …
The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment
Poly (ADP-ribose) polymerase (PARP) inhibitors are used in the treatment of BRCA-deficient
cancers, with treatments currently extending toward other homologous recombination …
cancers, with treatments currently extending toward other homologous recombination …
Advances and perspectives of PARP inhibitors
M Yi, B Dong, S Qin, Q Chu, K Wu, S Luo - Experimental hematology & …, 2019 - Springer
DNA damage repair deficiency leads to the increased risk of genome instability and
oncogenic transformation. In the meanwhile, this deficiency could be exploited for cancer …
oncogenic transformation. In the meanwhile, this deficiency could be exploited for cancer …
The ubiquitin ligase TRIP12 limits PARP1 trapping and constrains PARP inhibitor efficiency
PARP inhibitors (PARPi) cause synthetic lethality in BRCA-deficient tumors. Whether
specific vulnerabilities to PARPi exist beyond BRCA mutations and related defects in …
specific vulnerabilities to PARPi exist beyond BRCA mutations and related defects in …
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer
M Chiappa, F Guffanti, F Bertoni, I Colombo… - Drug Resistance …, 2021 - Elsevier
Ovarian cancer is the fifth cause of cancer-related deaths in women with high grade serous
carcinoma (HGSOC) representing the most common histological subtype. Approximately …
carcinoma (HGSOC) representing the most common histological subtype. Approximately …
Poly (ADP-ribose) polymerase (PARP) inhibitors and radiation therapy
Poly (ADP-ribose) polymerase-1 (PARP1) is a DNA repair enzyme highly expressed in the
nuclei of mammalian cells, with a structure and function that have attracted interest since its …
nuclei of mammalian cells, with a structure and function that have attracted interest since its …
PET imaging of PARP expression using 68Ga-labelled inhibitors
X Wang, W Liu, K Li, K Chen, S He, J Zhang… - European Journal of …, 2023 - Springer
Purpose Imaging the PARP expression using 18F probes has been approved in clinical
trials. Nevertheless, hepatobiliary clearance of both 18F probes hindered their application in …
trials. Nevertheless, hepatobiliary clearance of both 18F probes hindered their application in …
Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma
M Schick, L Zhang, S Maurer, HC Maurer… - Nature …, 2022 - nature.com
SUMOylation is a post-translational modification of proteins that regulates these proteins'
localization, turnover or function. Aberrant SUMOylation is frequently found in cancers but its …
localization, turnover or function. Aberrant SUMOylation is frequently found in cancers but its …